RxDoctor Payments Data

Tuanh Tonnu, MD

Gastroenterology · Gaithersburg, MDNPI 1083723878

Payments from drug & device makers

$3,278in general payments, 2019–2025

Across 139 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • AbbVie$306
  • Madrigal Pharmaceuticals$162
  • AstraZeneca$125
  • Covidien LP$100
  • Braintree Laboratories, Inc.$98
  • plus $518 from 13 others

What the payments were for

  • Food & beverage$3,23899%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,278 in reported general payments places this provider in the 50th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$146,085
Medicare patients
386
Services billed
1,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate32$48,091
Entecavir62$22,544
VemlidyTenofovir Alafenamide14$20,404
CanasaMesalamine13$14,858
ClenpiqSod Picosulf/Mag Ox/Citric Ac74$12,689
JardianceEmpagliflozin13$11,377
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates61$3,728
Rosuvastatin Calcium39$2,710
Amlodipine Besylate273$2,163
Omeprazole187$1,885
Colchicine13$1,735
Atorvastatin Calcium143$1,594
Metformin Hcl109$1,036
Losartan Potassium102$1,001
Famotidine76$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$48$48,09132 claims
GileadVemlidy$1,969$20,40414 claims
Ironwood Pharmaceuticals, IncCanasa$12$14,85813 claims
Ferring Pharmaceuticals Inc.Clenpiq$17$12,68974 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Gaithersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →